Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Mais filtros








Base de dados
Intervalo de ano de publicação
1.
Microbiol Spectr ; 10(3): e0005822, 2022 06 29.
Artigo em Inglês | MEDLINE | ID: mdl-35658712

RESUMO

Cefazolin, an active in vitro agent against Escherichia coli, is used to treat urinary and biliary tract infections. Cefazolin is used widely as an antibiotic, and the increase in the emergence of cefazolin-resistant E. coli in many countries is a major concern. We investigated the changes in the susceptibility of E. coli clinical isolates to cefazolin following exposure. A total of 88.9% (16/18 strains) of the strains acquired resistance to cefazolin. All strains with an MIC to cefazolin of 2 µg/mL became resistant. The expression of chromosomal ampC (c-ampC) increased up to 209.1-fold in the resistant strains. Moreover, 11 of the 16 E. coli strains (68.8%) that acquired cefazolin resistance maintained the resistant phenotype after subculture in cefazolin-free medium. Therefore, the acquisition and maintenance of cefazolin resistance in E. coli strains were associated with the overexpression of c-ampC. Mutations in the c-ampC attenuator regions are likely to be maintained and are one of the key factors contributing to the increase in the number of cefazolin-resistant E. coli worldwide. IMPORTANCE This study is the first to demonstrate that mutations in the chromosomal-ampC attenuator region are responsible for the emergence of cefazolin resistance in Escherichia coli strains. The resistance was maintained even after culturing E. coli without cefazolin. This study highlights one of the key factors contributing to the increase in the number of cefazolin-resistant E. coli strains, which can pose a considerable challenge for treating common infections, such as urinary tract infections.


Assuntos
Infecções por Escherichia coli , Escherichia coli , Antibacterianos/farmacologia , Antibacterianos/uso terapêutico , Proteínas de Bactérias/genética , Proteínas de Bactérias/metabolismo , Cefazolina/metabolismo , Cefazolina/farmacologia , Cefazolina/uso terapêutico , Escherichia coli/metabolismo , Infecções por Escherichia coli/tratamento farmacológico , Humanos , Testes de Sensibilidade Microbiana , beta-Lactamases/genética
3.
J Am Chem Soc ; 134(43): 18101-8, 2012 Oct 31.
Artigo em Inglês | MEDLINE | ID: mdl-23057606

RESUMO

Introducing substituents onto SWNT sidewalls increases their solubility and tunes their properties. Controlling the degree of functionalization is important because the addition of numerous functional groups on the sidewall degrades their intrinsic useful electronic properties. We examined the synthesis and characterization of sidewall-functionalized SWNTs in this study. The functionalized SWNTs ((1)R-SWNTs-(2)R) were prepared in a one-pot reaction of SWNTs with alkyllithium ((1)RLi) followed by alkyl bromide ((2)RBr). The functionalized SWNTs were characterized by the absorption and Raman spectroscopy and thermogravimetric analysis. Not only the total number of functional groups introduced on the SWNT sidewall (formula mass: (1)R = (2)R) but also the ratio of (2)R to (1)R in the functionalized SWNTs (formula mass: (1)R ≠ (2)R) having two different substituents were clarified using the relation between results of Raman spectroscopy and thermogravimetric analysis. Results show that the degree of functionalization of (2)R to (1)R in (1)R-SWNTs-(2)R can be well controlled by the bulkiness of the alkyl groups of (1)RLi and (2)RBr. Moreover, substituent effects of reductive alkylation and reductive silylation of SWNTs via Birch reduction were investigated.

SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA